Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...
Arvinas, Pfizer & Rigel’s Veppanu licensing deal is now active after U.S. antitrust clearance—$70M upfront plus up to $320M ...
12don MSN
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.
The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.
Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance ...
The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer China's ...
Chinese biotech Zai Lab Limited (ZLAB) announced late Monday that Chinese regulators approved its antibody-drug conjugate ...
Pfizer CEO Albert Bourla joins 'Squawk Box' to discuss the company's recent announcement about the lung cancer drug that has shown promising results on slowing the progression of the disease.
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results